Citigroup Inc Acadia Pharmaceuticals Inc Call Options Transaction History

Citigroup Inc

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 09, 2024	BUY	$20.78 - $31.77 $567,294 - $867,321	27,300 New	27,300 $854,000
Q1 2023 May 11, 2023	BUY	$16.32 - $20.92 $323,136 - $414,216	19,800 Added 66.0%	49,800 $937,000
Q4 2022 Feb 09, 2023	BUY	$14.2 - $18.63 $426,000 - $558,900	30,000 New	30,000 $477,000
Q2 2022 Aug 10, 2022	SELL	$13.01 - $27.22 $560,731 - $1.17 Million	-43,100 Reduced 63.29%	25,000 $352,000
Q1 2022 May 12, 2022	BUY	$20.94 - $27.5 $1.43 Million - $1.87 Million	68,100 New	68,100 $1.65 Million

279

156M

901K

314K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.76B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.